A novel development of liver-targeted androgen therapy for sarcopenia and synergistic benefit of resistance training in elderly

Phase 3

• Conditions: Sarcopenia; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12619001408178
• Lead Sponsor: SW Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-14
• Last Update Posted: 22 October 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 212

Inclusion Criteria

Community dwellers with sarcopenia but independent mobility. Sarcopenia will be defined by established clinical criteria: handgrip strength of 37 kg or less for men and 21 kg or less for women; or 12 seconds or more to rise 5 times from a chair with arms folded on the chest. Participants should be able to walk at least 10 m and climb at least one stair step without assistance.

Exclusion Criteria

Overt cardiac failure, active non-skin malignancy, diabetes mellitus, uncontrolled hypertension (systolic BP > 160 mmHg), end-stage kidney or liver failure, recent fractures, neurological impairments, joint replacements, planned surgery within next 6 months, and BMI>35 kg/m2.

Study & Design

• Study Type: Interventional
• Study Design: Not specified